1. Finland, a Global Testbed for Personalized Cancer Research?
FI/OTHE/1709/0033

2. General Manager Roche Oy
Maturin Tchoumi
General Manager Roche Oy
FI/ROCH/1702/0031
FI/ROCH/1704/0061(1)

3. Driving discovery GLOBAL #1 investor in healthcare R&D
EUROPE
4.192 billion CHF total investment in R&D in 2016
924 scientists within pRED across Region Europe in 2017
GLOBAL
#1 investor in healthcare R&D
#7 investor in R&D (all industries)
9.915 billion CHF invested in R&D in 2016
#1 provider of cancer medicines
A biotech leader – over 120 years of scientific research at our core
Decentralised structure – enabling local markets to leverage local insights
Leader in personalised healthcare - combine strengths of Pharmaceuticals and Diagnostics

4. Finland, a Global Testbed for Personalized Cancer Research?
Mallimaa 2020
Finland, a Global Testbed for
Personalized Cancer Research?

5. Healthcare mega trends
Increased development spend, accelerated development timelines and increased complexity of science
Industry is evolving: health and technology sectors will continue to converge. Personalized healthcare and big data will continue to transform medicine
Europe is a cauldron of innovation, but with complex market, political and cultural archetypes all within one geography
Price and cost pressures: European countries are combining negotiation strengths with innovative access strategies and pricing solutions
Reduced product differentiation: only 25% of upcoming launches show significant differentiation / treat diseases with high burden
Declining blockbuster model and rise in specialty medicines for rare diseases (75% of pharma pipelines)
People continue to expect more. Stakeholders have access to the internet 24/7, resulting in an oversaturation of information
and increase in demand
Societal and payer expectations have shifted: prevention or cure over treatment: more caution around ‘true’ innovation

6. 1 Patient, 1 Tumour 1 Profile, More Options
Revolution of Cancer Care Cancer care is becoming more personalised, moving towards an individualised treatment plan for each patient
Chemotherapy
No / few biomarkers
1 Patient Group,
1 Biomarker, 1 Drug
1 Patient, 1 Tumour 1 Profile, More Options
Advances in cancer biology are driving a future where cancer care is becoming increasingly personalised 6

7. Access meaningful data Realise value from insights
Driving a more sustainable approach to R&D and improved patient outcomes
More efficient and efficient R&D
Improved patient outcomes
Advanced analytics of integrated data
Diagnostic Data
Clinical Trial Data
Real World Data
Access meaningful data
Create insights
Realise value from insights 7

8. What makes Finland a potential Personalized Cancer Research?
Mallimaa 2020
What makes Finland a potential
Global Testbed for
Personalized Cancer Research?

9. Finland 1. Benefit of homogeneous population
2. Tradition of high quality science, robust medical practice and infrastructure
Top quality researchers with international networks
Willingness for public-private collaboration (global pharma & hospital partnership agreements)
One stop shops for collaboration (FICAN)
Eight world-class biobanks, electronic medical records and registeries (cancer)
Real world data opportunities (secondary data use legislation)
3. Early and full access to transformative medicine needs to be achieved